ype 1 diabetics, armed with glucose meters and insulin pens, are caught in a delicate high-wire act. Too much glucose wreaks havoc on nerves and blood vessels, while too little causes dizziness and nausea. A Cleveland biotech company is trying to change that by delivering insulin to the liver, where it naturally goes.
Diasome has three phase 2 clinical trials in progress testing nanoparticles known as hepatocyte-directed vesicles. These particles, smaller than the period at the end of this sentence, stick to insulin like Velcro and bring it to the liver. Diasome believes its approach will better manage patients’ blood sugar than administering insulin alone.